Here are 1-3 brief analogies for ARS Pharmaceuticals:

• Think of it like Insulet (makers of the Omnipod tubeless insulin pump), but for epinephrine, making emergency allergy treatment needle-free.
• It's a pharmaceutical company aiming to be the 'EpiPen of nasal sprays' for severe allergic reactions.
• Similar to how DexCom simplified diabetes management with continuous glucose monitors, ARS Pharmaceuticals aims to simplify emergency allergy treatment with a nasal spray.

• Neffy: A low-dose intranasal epinephrine nasal spray designed for patients at-risk of severe allergic reactions.

Major Customers of ARS Pharmaceuticals (SPRY):

ARS Pharmaceuticals, Inc. (SPRY) is currently a pre-commercial stage biopharmaceutical company. Its lead product, Neffy (intranasal epinephrine spray), has not yet received full regulatory approval from the U.S. Food and Drug Administration (FDA) for commercial sale. As such, the company does not currently have major customers purchasing its product for revenue generation.

However, once Neffy receives regulatory approval and is commercialized, ARS Pharmaceuticals would be expected to sell its product primarily to other companies within the established pharmaceutical distribution and healthcare ecosystem. These major prospective customer categories, and examples of companies typically found within them, would include:

• Pharmaceutical Wholesalers and Distributors: These companies purchase pharmaceutical products from manufacturers and distribute them to pharmacies, hospitals, and other healthcare providers. Examples include:
  • McKesson Corporation (NYSE: MCK)
  • Cardinal Health (NYSE: CAH)
  • AmerisourceBergen (NYSE: ABC)
• Large Pharmacy Chains: Retail pharmacy chains purchase medications for dispensing directly to patients through their network of pharmacies. Examples include:
  • CVS Health (NYSE: CVS)
  • Walgreens Boots Alliance (NASDAQ: WBA)
• Hospitals and Integrated Delivery Networks (IDNs): Hospitals and large healthcare systems purchase medications for use within their facilities and for dispensing to patients. While specific names are numerous and vary by region, this represents a significant customer segment for specialized medications.

• AptarGroup, Inc. (Symbol: ATR)
• Lonza Group AG (Symbol: LONN)
• Kindeva Drug Delivery L.P.
• Catalent, Inc. (Symbol: CTLT)

Richard Lowenthal, Co-Founder, President, CEO & Director

Richard Lowenthal is a co-founder of ARS Pharmaceuticals and has served as its President, Chief Executive Officer, and a member of its Board of Directors since the company's inception in 2015.

Kathleen Scott, Chief Financial Officer

Kathleen Scott serves as the Chief Financial Officer of ARS Pharmaceuticals.

Eric Karas, Chief Commercial Officer

Eric Karas has been the Chief Commercial Officer of ARS Pharmaceuticals since April 2022. Prior to this role, he served as Vice President and General Manager of Commercial, North America at Emergent from 2018 to March 2022.

Justin Chakma, Chief Business Officer

Justin Chakma has served as ARS Pharmaceuticals' Chief Business Officer since June 2019. Before joining ARS Pharmaceuticals, he was the VP, Head of Business Development and Strategy at Vedanta Biosciences from 2018 to May 2019.

Brian T. Dorsey, Chief Operating Officer

Brian T. Dorsey has held the position of Chief Operating Officer at ARS Pharmaceuticals since December 2022. Previously, he served as the company's Senior Vice President of Operations and Project Management from 2018 to December 2022.

1. Dependence on Neffy Commercialization: ARS Pharmaceuticals is highly reliant on the successful commercialization of Neffy, its intranasal epinephrine spray. Key challenges include achieving broad market acceptance, securing favorable insurance coverage, and overcoming administrative hurdles such as prior authorization requirements. Any delays or setbacks in these areas, or if the product does not gain sufficient traction against established injectable epinephrine products, could materially and adversely affect the company's business, financial condition, and share price.
2. Financial Performance and Funding Needs: The company has incurred significant losses since its inception and continues to operate at a loss, primarily due to heavy selling, general, and administrative (SG&A) expenses associated with the launch and promotion of Neffy. ARS Pharmaceuticals will require additional funding to support its ongoing operations and commercialization efforts. A failure to secure adequate capital could lead to delays in product development, reduced operational scope, or the elimination of product lines.
3. Regulatory and Manufacturing Risks: Although Neffy has received regulatory approvals in several regions, the company faces ongoing risks related to maintaining these approvals, obtaining new approvals in additional geographies, and expanding indications. For example, there were initial FDA delays for Neffy, requesting more data on repeat doses. Furthermore, ARS Pharmaceuticals is dependent on third-party manufacturers for critical components for Neffy. An antitrust lawsuit filed by ARS Pharmaceuticals against AptarGroup, alleging an illegal monopoly over key components, highlights a significant supply chain vulnerability and the potential for inflated costs or disrupted supply.

ARS Pharmaceuticals' main product, Neffy, an intranasal epinephrine spray for severe allergic reactions, targets significant addressable markets.

In the **United States**, the initial addressable market for Neffy is estimated to be approximately $3 billion in annual net sales, focusing on 6.5 million patients who are currently prescribed epinephrine. There is an additional potential market of $7 billion for 13.5 million diagnosed patients not yet prescribed epinephrine. Neffy's annual revenue in the U.S. is projected to reach $722 million by 2033.

For **Europe and Canada**, the combined market for epinephrine devices, including intranasal options like Neffy, is valued at approximately $230 million. Analysts anticipate that Neffy could generate over $400 million in peak sales within these licensed territories.

The broader **global anaphylaxis treatment market**, where Neffy competes, was approximately $3.57 billion in 2024 and is projected to reach $6.27 billion by 2033, growing at a Compound Annual Growth Rate (CAGR) of 6.4% from 2025 to 2033. Another estimate indicates the global epinephrine market size was $2.77 billion in 2024 and is expected to reach $5.74 billion by 2032, with a CAGR of 9.57% from 2025 to 2032.

Specifically for the **U.S. epinephrine for anaphylaxis treatment market**, it was valued at $1.04 billion in 2023 and is expected to grow to $2.07 billion by 2032, with a CAGR of 12.9% during the forecast period.

ARS Pharmaceuticals (NASDAQ: SPRY) anticipates several key drivers to fuel its future revenue growth over the next 2-3 years, primarily centered around the continued commercialization and expansion of its flagship product, Neffy (epinephrine nasal spray).

1. Expanded U.S. Market Penetration and Prescription Growth for Neffy

A primary driver of revenue growth for ARS Pharmaceuticals will be the continued increase in Neffy prescriptions and the expansion of its market share within the United States. Neffy, approved by the FDA in August 2024 for both adult and pediatric use, recorded $72.2 million in U.S. net product revenue in its first full year of commercial sales in 2025, indicating a strong market entry. The company expects initial prescriptions to begin renewing in 2026 as the product reaches expiration, coupled with a continued rise in new Neffy patients. To support this growth, ARS Pharmaceuticals plans to expand its sales force from 106 to 150 representatives starting in the second quarter of 2026, aiming to increase prescribing depth among high-prescribing allergists and their staff. Furthermore, strategic efforts are focused on reducing prior authorization barriers and securing unrestricted access with major payers, building on the approximately 93% overall commercial coverage achieved by the end of 2025. Direct-to-consumer (DTC) advertising campaigns and the "Get Neffy on Us" program are also expected to drive greater awareness and adoption of Neffy.

2. International Commercialization of Neffy

The company's expansion into international markets is another significant revenue driver. ARS Pharmaceuticals expects to receive regulatory approval for Neffy in Canada in the second quarter of 2026, with an official commercial launch anticipated later that year through its partnership with ALK. This represents a crucial step in expanding Neffy's presence in the North American market. Beyond Canada, international partners are actively pursuing regulatory approvals in other key regions, including Europe, China, Japan, and Australia, with partner-led launches projected to occur in 2026. These new market entries are expected to contribute to a diversified revenue stream over the next few years.

3. Potential Label Expansion for Neffy into New Indications

The potential for Neffy to gain approval for new indications beyond severe allergic reactions presents a substantial long-term revenue growth opportunity. ARS Pharmaceuticals is currently conducting a Phase 2b trial to evaluate its intranasal epinephrine technology as a treatment for acute flares of chronic spontaneous urticaria (CSU). Interim data from this trial is anticipated in the second half of 2026, with the potential initiation of a single pivotal efficacy study targeted for mid-2027. Analysts have indicated that Neffy could achieve significantly higher peak revenues if it successfully expands its label into areas like urticaria, which some estimate as a multi-billion dollar annual market opportunity. This pipeline development could unlock new patient populations and significantly broaden Neffy's revenue potential within the 2-3 year timeframe and beyond.

Share Repurchases

No information available regarding share repurchases or authorized future share repurchases for ARS Pharmaceuticals over the last 3-5 years.

Share Issuance

• ARS Pharmaceuticals has funded its operations, in part, through the issuance of common stock and a private placement of convertible preferred stock.
• The company's operations were also funded by proceeds from its merger with Silverback in November 2022.
• An automatic shelf registration statement on Form S-3ASR was filed in January 2025, which allows the company to offer and sell various securities, including common stock, in future offerings.

Inbound Investments

• In November 2024, ARS Pharmaceuticals received a non-refundable, upfront cash payment of $145 million from ALK-Abelló as part of a licensing agreement.
• The company anticipates receiving approximately $5 million in milestone payments from ALK in both the second and fourth quarters of 2025.
• Revenue has also been generated from collaboration and supply agreements with international partners, including Alfresa in Japan, Pediatrix in China, and Seqirus in Australia and New Zealand.

Outbound Investments

No information available regarding significant outbound investments made by ARS Pharmaceuticals in other companies over the last 3-5 years.

Capital Expenditures

• Annual capital expenditures were $0.06 million in 2021, $0.20 million in 2022, $0.18 million in 2023, and $0.56 million in 2024.
• For the full year 2025, capital expenditures amounted to $0.339 million.
• In the second quarter of 2025 (June 2025), quarterly capital expenditures were $5.8 million.